lifestyle.ribbon.co

Author: BioXcel Therapeutics

BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

May 15, 2026
BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting

April 17, 2026
BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions

April 8, 2026
BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions

April 8, 2026
BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting

April 1, 2026
BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting

April 1, 2026
BioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI® Approval in Outpatient Setting

March 27, 2026
BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering

March 12, 2026
BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering

March 12, 2026
BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering

March 11, 2026